Lazard Asset Management
NVAX icon

Lazard Asset Management’s Novavax NVAX Stock Holding History

Lazard Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,632
Closed -$178K – 2162
2025
Q2 		$178K Buy
28,632
+7,792
+37% +$51.6K ﹤0.01% 1728
2025
Q1 		$132K Buy
20,840
+15,906
+322% +$131K ﹤0.01% 1741
2024
Q4 		$39K Sell
4,934
-3,718
-43% -$35.8K ﹤0.01% 2018
2024
Q3 		$108K Buy
+8,652
New +$112K ﹤0.01% 1765
2022
Q3 		– Sell
-1,214
Closed -$62K – 2480
2022
Q2 		$62K Sell
1,214
-5,455
-82% -$283K ﹤0.01% 1713
2022
Q1 		$491K Buy
6,669
+4,725
+243% +$421K ﹤0.01% 1107
2021
Q4 		$278K Sell
1,944
-4,761
-71% -$818K ﹤0.01% 1207
2021
Q3 		$1.39M Buy
6,705
+5,851
+685% +$1.29M ﹤0.01% 983
2021
Q2 		$181K Buy
+854
New +$156K ﹤0.01% 1229
2021
Q1 		– Sell
-3,835
Closed -$427K – 1959
2020
Q4 		$427K Buy
3,835
+3,765
+5,379% +$400K ﹤0.01% 1002
2020
Q3 		$7K Buy
+70
New +$8.53K ﹤0.01% 1514

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lazard Asset Management's NVAX Position: Q3 2025 in Review

Lazard Asset Management sold out of Novavax (NVAX) in Q3 2025, closing a stake of 28,632 shares — an estimated $178K sold.

Lazard Asset Management first reported a position in NVAX in Q3 2020 and held it in 11 quarters. The position peaked at $1.39M in Q3 2021. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

  • Lazard Asset Management reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 28,632 Novavax shares in Q3 2025, an estimated $178K.
  • Lazard Asset Management first reported a position in Novavax in Q3 2020 and held it in 11 quarters.
  • Lazard Asset Management's Novavax position peaked at $1.39M in Q3 2021.
  • 249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.